Health Care Stocks Performance: Health care stocks have rebounded in 2025, driven by improved valuations and earnings, despite lingering concerns about mid-single-digit growth in the sector.
Investment Trends: Investors are increasingly shifting focus from high-risk biotech to med tech and health care services, seeking recurring revenue models and scalable opportunities without the same drug development risks.
Company Highlights: Intuitive Surgical and Edwards Lifesciences are noted for their strong growth in the health care sector, with Intuitive Surgical benefiting from rising global procedure volumes and Edwards focusing on less invasive cardiac procedures.
IQVIA's Growth: IQVIA is gaining traction in data analytics and clinical trial management, becoming essential for pharmaceutical companies as drug pipelines grow more complex, while also benefiting from improved financial conditions and increased demand for its services.
Wall Street analysts forecast IQV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IQV is 258.31 USD with a low forecast of 215.00 USD and a high forecast of 290.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
Wall Street analysts forecast IQV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IQV is 258.31 USD with a low forecast of 215.00 USD and a high forecast of 290.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
3 Hold
0 Sell
Strong Buy
Current: 239.430
Low
215.00
Averages
258.31
High
290.00
Current: 239.430
Low
215.00
Averages
258.31
High
290.00
TD Cowen
Charles Rhyee
Hold
maintain
$215 -> $245
2026-01-22
Reason
TD Cowen
Charles Rhyee
Price Target
$215 -> $245
AI Analysis
2026-01-22
maintain
Hold
Reason
TD Cowen analyst Charles Rhyee raised the firm's price target on Iqvia to $245 from $215 and keeps a Hold rating on the shares. The firm adjusted targets in the contract research organization space as part of a Q4 preview. TD generally expects solid Q4 prints and sees potential for 2026 outlooks to "represent a clearing event for operating conditions."
Mizuho
Outperform
maintain
$250 -> $266
2026-01-09
Reason
Mizuho
Price Target
$250 -> $266
2026-01-09
maintain
Outperform
Reason
Mizuho raised the firm's price target on Iqvia to $266 from $250 and keeps an Outperform rating on the shares. The firm updated targets in the healthcare facilities and managed care group as part of a Q4 preview. Mizuho's physician survey indicated healthcare utilization growth trends decelerated sequentially despite easier year-over-year comps, which could indicate trend is peaking, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IQV
Unlock Now
Truist
Jailendra Singh
Buy
maintain
$265 -> $290
2026-01-08
Reason
Truist
Jailendra Singh
Price Target
$265 -> $290
2026-01-08
maintain
Buy
Reason
Truist analyst Jailendra Singh raised the firm's price target on Iqvia to $290 from $265 and keeps a Buy rating on the shares. Iqvia enters 2026 with stronger demand visibility and a healthier operating backdrop, supported by improved book-to-bill ratios, RFP flow, and pipeline clarity, alongside stable TAS trends and continued growth in Consulting & Analytics, the analyst tells investors in a research note. Margins are expected to modestly expand through automation and efficiencies, reinforcing Iqvia's position as a preferred CRO name due to its scale, diversified clients, and financial flexibility.
UBS
Dan Leonard
Buy
maintain
$250 -> $280
2026-01-08
Reason
UBS
Dan Leonard
Price Target
$250 -> $280
2026-01-08
maintain
Buy
Reason
UBS analyst Dan Leonard raised the firm's price target on Iqvia to $280 from $250 and keeps a Buy rating on the shares.
About IQV
IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. It offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
